Copyright © 2012 Fernando Espi Martinez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. M. Dose and H. D. Tempel, “Abuse potential of anticholinergics,” Pharmacopsychiatry, vol. 33, no. 1, pp. 43–46, 2000. View at Publisher · View at Google Scholar · View at Scopus
2. R. F. Grace, “Benztropine abuse and overdose—case report and review,” Adverse Drug Reactions and Toxicological Reviews, vol. 16, no. 2, pp. 103–112, 1997. View at Scopus
3. Y. Tamura, S. Chiba, H. Takasaki, K. Tabata, Y. Ishimaru, and T. Ishimoto, “Biperiden-induced delirium model in rats: a behavioral and electroencephalographic study,” Brain Research, vol. 1115, no. 1, pp. 194–199, 2006. View at Publisher · View at Google Scholar · View at Scopus
4. S. White, “The neuropathogenesis of delirium,” Reviews in Clinical Gerontology, vol. 12, no. 1, pp. 62–67, 2002. View at Publisher · View at Google Scholar · View at Scopus
5. N. Buhrich, A. Weller, and P. Kevans, “Misuse of anticholinergic drugs by people with serious mental illness,” Psychiatric Services, vol. 51, no. 7, pp. 928–929, 2000. View at Publisher · View at Google Scholar · View at Scopus
6. L. Chamorro García, “Dependence on anticholinergics among schizophrenics. Iatrogenic disease or self-medication?” Actas Luso-Espanolas de Neurologia Psiquiatria y Ciencias Afines, vol. 19, no. 6, pp. 298–303, 1991. View at Scopus
7. R. M. Schulte, “Abuse of biperiden as a participating factor in polytoxicomania,” Psychiatrische Praxis, vol. 15, no. 2, pp. 53–56, 1988. View at Scopus
8. P. A. Soler Insa, “Abuso y Dependencia de Farmacos Antiparkisonianos,” Trastornos Adictivos, vol. 2, no. 3, pp. 172–176, 2000.
9. D. J. Meagher, M. Moran, B. Raju et al., “Phenomenology of delirium: assessment of 100 adult cases using standardised measures,” British Journal of Psychiatry, vol. 190, pp. 135–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
10. M. J. Burns, C. H. Linden, A. Graudins, R. M. Brown, and K. E. Fletcher, “A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning,” Annals of Emergency Medicine, vol. 35, no. 4, pp. 374–381, 2000. View at Scopus
11. K. A. Hadidi, “Development of a screening method for the most commonly abused anticholinergic drugs in Jordan; Trihexyphenidyl, procyclidine and biperiden,” Legal Medicine, vol. 6, no. 4, pp. 233–241, 2004. View at Publisher · View at Google Scholar · View at Scopus
12. P. Gjerden, J. G. Bramness, and L. Slørdal, “The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study,” British Journal of Clinical Pharmacology, vol. 67, no. 2, pp. 228–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
13. W. W. Fleischhacker, C. Barnas, V. Gunther, U. Meise, C. Stuppack, and B. Uterweger, “Mood-altering effects of biperiden in healthy volunteers,” Journal of Affective Disorders, vol. 12, no. 2, pp. 153–157, 1987. View at Scopus
14. R. C. Pierce and V. Kumaresan, “The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?” Neuroscience and Biobehavioral Reviews, vol. 30, no. 2, pp. 215–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
15. D. B. Lester, T. D. Rogers, and C. D. Blaha, “Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders,” CNS Neuroscience and Therapeutics, vol. 16, no. 3, pp. 137–162, 2010. View at Publisher · View at Google Scholar · View at Scopus